帕奴拉明 | 80349-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 帕奴拉明
• 中文别名: 萘哌拉明
• 英文名称: Panuramine
• 英文别名: 1-benzoyl-3-[1-(naphth-2-ylmethyl)piperid-4-yl]urea；N-[[1-(naphthalen-2-ylmethyl)piperidin-4-yl]carbamoyl]benzamide
• CAS: 80349-58-2
• 化学式: C₂₄H₂₅N₃O₂
• 分子量: 387.481
• InChiKey: AQFFJGJVFJCQQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  帕奴拉明 以 sodium hydroxide 为溶剂， 以to give [1-(naphth-2-ylmethyl)piperid-4-yl]urea (m.p. 183°-5° C.)的产率得到[1-(naphth-2-yl-methyl)piperid-4-yl]urea
  参考文献：
  名称：

  3-benzoyl-1-[(oxo or thioheteroaryl-ylalkyl)-piperid-4-yl]ureas and

  摘要：

  本发明涉及公式##STR1##化合物的制备，以及其酸加成物和季铵盐，其中点线表示可选键，Ar表示公式##STR2##的环系统，其中Q为O，S，-CR.sup.7 =CR.sup.8 -，-N=CR.sup.8 -和-N=N-; 当存在时，R.sup.4，R.sup.5和R.sup.6，以及R.sup.7和R.sup.8，均表示氢或从较低的烷基，较低的烯基，较低的烷氧基，NO.sub.2，NH.sub.2，卤代较低烷基，羟基较低烷基，氨基较低烷基，取代氨基，卤素，较低烷氧羰基，氰基，CONH.sub.2和羟基中选择的取代基; 另外，当相邻的R.sup.4和R.sup.5或R.sup.6和R.sup.8存在时，它们与它们所附着的碳原子一起也表示一个融合的五元或六元环或杂环，可选地携带一个或多个上述定义的取代基; R是一个可选地取代的芳基或杂环芳基基团或含有5到7个碳原子的环烷基基团; R.sup.1，R.sup.2，R.sup.3和R.sup.9分别为氢或较低烷基; n为0或1，X为.dbd.O，.dbd.S或.dbd.NH; Y为-O-或直接键，Z为-CO-或-CH.sub.2-，但是当Ar为未取代的苯丙基且R.sup.9为氢时，Y为-O-。公式I的化合物具有精神活性，并可用作抗抑郁剂。

  公开号：

  US04722930A1
• 作为产物：
  描述：

  4-Benzoylureido piperidine 、 2-溴甲基萘 在 三乙胺 作用下， 以 N-甲基乙酰胺 、 乙醇 、 水 为溶剂， 生成 帕奴拉明
  参考文献：
  名称：

  Pyridyl- and/or pyridoyl-(piperid-4-yl) ureas and analogues thereof

  摘要：

  该发明涉及化合物的制备，其化学式为##STR1##以及其酸加成物和季铵盐，其中虚线代表一个可选键，Ar代表一个化学式为##STR2##的环系统，其中Q为O、S、--CR^7.dbd.CR^8--、--N.dbd.CR^8--和--NM.dbd.N--; R^4、R^5和R^6; 当R^7和R^8存在时，每个都代表氢或从较低烷基、较低烯基、较低烷氧基、NO2、NH2、卤代较低烷基、羟基较低烷基、氨基较低烷基、取代氨基、卤素、较低烷氧羰基、氰基、CONH2和羟基中选择的取代基; 此外，当相邻时，R^4和R^5或R^6和R^8，连同它们所连接的碳原子，也代表一个融合的五元或六元碳环或杂环，可选择携带一个或多个上述定义的取代基; R是一个可选择取代的芳基或杂环芳基基团或含有5至7个碳原子的环烷基基团; R^1、R^2、R^3和R^9分别是氢或较低烷基基团; n为0或1; X是.dbd.O、.dbd.S或.dbd.NY; Y是--O--或直接键，Z是--CO--或--CH2--，但当Ar为未取代的苯丙烯基且R^9为氢时，则v为--O--。化合物I的表现出精神活性，并可用作抗抑郁剂。

  公开号：

  US04806552A1

文献信息

• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2015066344A1

  公开（公告）日：2015-05-07

  Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

  提供了5-HT2C受体激动剂。还提供了用于体重管理、诱导饱腹感、减少食物摄入量、预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲）、睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停。还提供了包含选择性5-HT2C受体激动剂的组合物，可选地与辅助剂结合，以及用于减少个体尝试减少吸烟频率的吸烟频率；帮助个体戒除或减少使用烟草制品的个体戒除或减少使用烟草制品；帮助戒烟并预防相关体重增加；通过个体尝试戒烟来控制与戒烟相关的体重增加；通过个体尝试戒烟来减少与戒烟相关的体重增加；治疗尼古丁依赖、成瘾和/或戒断的个体尝试治疗尼古丁依赖、成瘾和/或戒断；或减少个体尝试戒除尼古丁使用的复发可能性，包括给予选择性5-HT2C受体激动剂，可选地与辅助剂结合。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DES RÉCEPTEURS 5-HT2C ET COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2016176177A1

  公开（公告）日：2016-11-03

  Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided in some embodiments are compositions comprising a compound herein, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a compound herein, optionally in combination with a supplemental agent.

  在某些实施例中提供了本文中的化合物。在某些实施例中还提供了用于体重管理、诱发饱腹感、减少食物摄入、预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理赌博、奖赏缺乏综合征、性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲）、睡眠障碍（包括失眠、睡眠结构紊乱和慢波睡眠障碍）、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停。在某些实施例中还提供了包含本文中的化合物的组合物，可选择地与辅助剂结合，并且提供了用于减少个体尝试减少吸烟频率的吸烟频率；帮助个体戒除或减少吸烟产品的使用；帮助戒烟并预防相关体重增加；通过个体试图戒烟来控制与戒烟相关的体重增加；通过个体试图戒烟来减少与戒烟相关的体重增加；治疗个体试图治疗尼古丁依赖、成瘾和/或戒断的尼古丁依赖、成瘾和/或戒断；或减少个体试图停止尼古丁使用的复发尼古丁使用的可能性，包括给予本文中的化合物，可选择地与辅助剂结合。
• Piperid-4-yl ureas and thio ureas used as antidepressant agents
  申请人：——

  公开号：US04563466A1

  公开（公告）日：1986-01-07

  The invention concerns the preparation of compounds of formula ##STR1## and acid addition and quaternary ammoniun salts thereof, wherein the dotted line represents an optional bond, Ar represents a ring system of formula ##STR2## in which Q is O, S, --CR.sup.7 .dbd.CR.sup.8 --, --N.dbd.CR.sup.8 -- and --N.dbd.N--; R.sup.4, R.sup.5 and R.sup.6, and R.sup.7 and R.sup.8 when present, each represent hydrogen or a substituent selected from lower alkyl, lower alkenyl, lower alkoxy, NO.sub.2, NH.sub.2, haloloweralkyl, hydroxyloweralkyl, aminoloweralkyl, substituted amino, halogen, loweralkoxycarbonyl, cyano, CONH.sub.2 and hydroxy; and additionally either R.sup.4 and R.sup.5 when adjacent or R.sup.6 and R.sup.8 when adjacent, together with the carbon atoms to which they are attached also represent a fused five or six membered carbocylic or heterocyclic ring optionally carrying one or more substituents as defined above; R is an optionally substituted aryl or heteroaryl radical or a cycloalkyl radical containing 5 to 7 carbon atoms; R.sup.1, R.sup.2, R.sup.3 and R.sup.9 are each hydrogen or a lower alkyl group; n is 0 or 1; X is .dbd.O, .dbd.S or .dbd.NH; Y is --O-- or a direct bond and Z is -- CO-- or --CH.sub.2 --, with the proviso that when Ar is unsubstituted phenyl and R.sup.9 is hydrogen then Y is --O--. The compounds of formula I exhibit psychotropic activity and are useful as antidepressants.

  该发明涉及化合物的制备的公式##STR1##以及其酸盐和季铵盐，其中虚线代表可选键，Ar代表公式##STR2##中的环系统，其中Q为O、S、--CR.sup.7 .dbd.CR.sup.8 --、--N.dbd.CR.sup.8 --和--N.dbd.N--; R.sup.4、R.sup.5和R.sup.6，以及R.sup.7和R.sup.8（存在时），每个代表氢或从较低烷基、较低烯基、较低烷氧基、NO.sub.2、NH.sub.2、卤代较低烷基、羟基较低烷基、氨基较低烷基、取代氨基、卤素、较低烷氧羰基、氰基、CONH.sub.2和羟基中选择的取代基；另外，当相邻时，R.sup.4和R.sup.5或R.sup.6和R.sup.8也代表与它们连接的碳原子一起表示一个融合的五元或六元碳环或杂环，该环可以携带一个或多个上述定义的取代基；R是一个可选择取代的芳基或杂环芳基基团或含有5至7个碳原子的环烷基基团；R.sup.1、R.sup.2、R.sup.3和R.sup.9分别是氢或较低烷基基团；n为0或1；X为.dbd.O、.dbd.S或.dbd.NH；Y为--O--或直接键，Z为--CO--或--CH.sub.2--，但如果Ar为未取代的苯基且R.sup.9为氢，则Y为--O--。公式I的化合物具有精神活性并可用作抗抑郁剂。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DES RÉCEPTEURS 5-HT2C, COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2018035477A1

  公开（公告）日：2018-02-22

  The present invention relates to compounds of Formula A and pharmaceutical compositions thereof that modulate the activity of the 5-HT2C receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a 5-HT2C receptor-mediated disorder, such as, weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction and the like, obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders, urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a compound herein, optionally in combination with a supplemental agent.

  本发明涉及式A的化合物及其药物组合物，可调节5-HT2C受体的活性。本发明的化合物及其药物组合物用于治疗5-HT2C受体介导的疾病，如体重管理、诱发饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾等，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停症。还提供含有本文中化合物的组合物，可选择性地与辅助剂组合使用。